BioSpace News Archive

Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) is pleased to announce the publication following peer-review of an article titled “Nanobodies to multiple spike variants and inhalation of nanobody-containing aerosols neutralize SARS-CoV-2 in cell culture and hamsters” in the prestigious scientific journal Antiviral Research.

Veradigm Inc. announced today that it will now offer a conversational artificial intelligence (AI) agent for Practice Fusion Billing Services, a Veradigm Network solution.

Corsair Pharma, Inc. today announced the appointment of George W. Mahaffey as Chief Executive Officer.

Know Labs, Inc. today announced it will host a webcast to review business updates and results for its fiscal year ended on September 30, 2023, on December 19, 2023, beginning at 1:30 pm PT.

Sumitomo Pharma America, Inc. (SMPA) today announced new data from the ongoing Phase 1/2 first-in-human study of DSP-5336, in patients with relapsed or refractory acute leukemia.

Biomea Fusion, Inc. presented positive clinical data for BMF-219, an investigational covalent menin inhibitor, in relapsed / refractory AML patients with menin-dependent mutations at the 65th American Society of Hematology (ASH) Annual Meeting.

Immix Biopharma, Inc today announced new clinical data from its Phase 1b/2a NEXICART-1 (NCT04720313) study of novel, autologous, BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy, NXC-201, in patients with relapsed/refractory AL Amyloidosis (R/R ALA) at an oral presentation by study investigator Moshe E. Gatt, MD at the 65th American Society of Hematology (ASH) Meeting being held in San Diego, CA

BSNSW, a key part of the national BreastScreen Australia Program, is a joint initiative funded by the Commonwealth, state and territory governments, and managed by the Cancer Institute NSW.

Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for patent application no. 18/100,396 entitled “New Pharmaceutical Compositions.”

MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (“MustGrow”) is pleased to announce the signing of a collaboration agreement (the “Agreement”) with Bayer AG (FSE: BAYN) (“Bayer”) covering soil applications of MustGrow’s mustard-based biocontrol technologies in Europe, Middle East and Africa, excluding home and garden, turf and ornamental applications.